(Q24240959)

title

Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension (English)

0 references

main subject

arterial hypertension

1 reference

Balraj S Heran

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6669255&resulttype=core&format=json

16 May 2020

Inderjit K Heran

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6669255&resulttype=core&format=json

16 May 2020

James M Wright

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6669255&resulttype=core&format=json

16 May 2020

Michelle M Y Wong

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6669255&resulttype=core&format=json

Cochrane Database of Systematic Reviews

16 May 2020

publication date

8 October 2008

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6669255&resulttype=core&format=json

16 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6669255&resulttype=core&format=json

16 May 2020

page(s)

CD003822

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6669255&resulttype=core&format=json

Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy

16 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

The effect of a losartan-based treatment regimen on isolated systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Effect of AT1 receptor blockade on endothelial function in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study. Tasosartan Investigators Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

The effects of KT3-671, a new angiotensin II (AT 1) receptor blocker in mild to moderate hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Candesartan cilexetil and renal hemodynamics in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Efficacy of valsartan in patients aged > or =65 years with systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

T-lymphocyte and plasma angiotensin-converting enzyme activity during enalapril and losartan administration in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003822.PUB2

The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group

21 January 2018

1 reference

12 December 2020

A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine

1 reference

12 December 2020

A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension

1 reference

12 December 2020

Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group.

1 reference

12 December 2020

Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators

1 reference

12 December 2020

Dose-response efficacy of valsartan, a new angiotensin II receptor blocker

1 reference

12 December 2020

The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Telmisartan Cough Study Group

1 reference

12 December 2020

Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension

1 reference

12 December 2020

ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension

1 reference

12 December 2020

A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesar

1 reference

12 December 2020

Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients With Mild to Moderate Hypertension

1 reference

12 December 2020

Candesartan cilexetil in hypertension: effects of six weeks' treatment on haemodynamics, baroreceptor sensitivity and the renin-angiotensin-aldosterone system

1 reference

12 December 2020

Blockade of angiotensin II type 1 receptors: effect on carotid and radial artery structure and function in hypertensive humans

1 reference

12 December 2020

A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators

1 reference

12 December 2020

Dose response and safety of telmisartan in patients with mild to moderate hypertension

1 reference

12 December 2020

Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial.

1 reference

12 December 2020

Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising

1 reference

12 December 2020

Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring

1 reference

12 December 2020

Losartan with hydrochlorothiazide in the treatment of hypertension.

1 reference

12 December 2020

A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension

1 reference

12 December 2020

Blood pressure effects of the angiotensin II receptor blocker, losartan

1 reference

12 December 2020

Controlling blood pressure throughout the day: issues in testing a new anti-hypertensive agent

1 reference

12 December 2020

Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Ambulatory Blood Pressure Monitoring Study Gro

1 reference

12 December 2020

The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension

1 reference

12 December 2020

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril

1 reference

12 December 2020

Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension

1 reference

12 December 2020

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril

1 reference

12 December 2020

The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population

1 reference

12 December 2020

24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring

1 reference

12 December 2020

The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group

1 reference

12 December 2020

1 reference

12 December 2020

Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators

1 reference

12 December 2020

10.1002/14651858.CD003822.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6669255&resulttype=core&format=json

release_yyjs24tngzbwjdry37jaubbizm

16 May 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yyjs24tngzbwjdry37jaubbizm

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6669255&resulttype=core&format=json

16 May 2020

PubMed publication ID

18843650

1 reference